These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 39375615)
1. Clinicopathological characteristics and prognosis of combined hepatocellular cholangiocarcinoma. Li Y; He D; Lu ZJ; Gu XF; Liu XY; Chen M; Tu YX; Zhou Y; Owen G; Zhang X; Jiang D BMC Cancer; 2024 Oct; 24(1):1232. PubMed ID: 39375615 [TBL] [Abstract][Full Text] [Related]
2. Expression of fibroblast growth factor receptor 2 (FGFR2) in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma: clinicopathological study. Sasaki M; Sato Y; Nakanuma Y Virchows Arch; 2024 Jun; 484(6):915-923. PubMed ID: 38532197 [TBL] [Abstract][Full Text] [Related]
3. Is nestin a diagnostic marker for combined hepatocellular-cholangiocarcinoma? Sasaki M; Sato Y; Nakanuma Y Histopathology; 2022 Apr; 80(5):859-868. PubMed ID: 35076959 [TBL] [Abstract][Full Text] [Related]
4. YAP and TAZ Heterogeneity in Primary Liver Cancer: An Analysis of Its Prognostic and Diagnostic Role. Van Haele M; Moya IM; Karaman R; Rens G; Snoeck J; Govaere O; Nevens F; Verslype C; Topal B; Monbaliu D; Halder G; Roskams T Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717258 [TBL] [Abstract][Full Text] [Related]
5. The clinical characteristics and prognostic factors of combined Hepatocellular Carcinoma and Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma after Surgical Resection: A propensity score matching analysis. Tang Y; Wang L; Teng F; Zhang T; Zhao Y; Chen Z Int J Med Sci; 2021; 18(1):187-198. PubMed ID: 33390787 [No Abstract] [Full Text] [Related]
6. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma. Murugesan K; Sharaf R; Montesion M; Moore JA; Pao J; Pavlick DC; Frampton GM; Upadhyay VA; Alexander BM; Miller VA; Javle MM; Bekaii Saab TS; Albacker LA; Ross JS; Ali SM JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34476330 [TBL] [Abstract][Full Text] [Related]
7. Tertiary lymphoid structures as a potential prognostic biomarker for combined hepatocellular-cholangiocarcinoma. Gong W; Zhang S; Tian X; Chen W; He Y; Chen L; Ding T; Ren P; Shi L; Wu Q; Sun Y; Chen L; Guo H Hepatol Int; 2024 Aug; 18(4):1310-1325. PubMed ID: 38767772 [TBL] [Abstract][Full Text] [Related]
8. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification. Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585 [TBL] [Abstract][Full Text] [Related]
9. The Dominant Component and Clinicopathological Characteristics of Combined Hepatocellular-cholangiocarcinoma After Radical Resection. Matsubara K; Kobayashi T; Tadokoro T; Namba Y; Fukuhara S; Oshita KO; Honmyo N; Kuroda S; Arihiro K; Ohdan H Anticancer Res; 2024 Oct; 44(10):4551-4559. PubMed ID: 39348996 [TBL] [Abstract][Full Text] [Related]
10. Radiological features and outcomes of combined hepatocellular-cholangiocarcinoma in patients undergoing surgical resection. Chi CT; Chau GY; Lee RC; Chen YY; Lei HJ; Hou MC; Chao Y; Huang YH J Formos Med Assoc; 2020 Jan; 119(1 Pt 1):125-133. PubMed ID: 30876788 [TBL] [Abstract][Full Text] [Related]
11. Combined hepatocellular-cholangiocarcinoma: An analysis of clinicopathological characteristics after surgery. Zhang H; Yu X; Xu J; Li J; Zhou Y Medicine (Baltimore); 2019 Sep; 98(38):e17102. PubMed ID: 31567946 [TBL] [Abstract][Full Text] [Related]
12. Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance? Wang X; Wang W; Ma X; Lu X; Li S; Zeng M; Xu K; Yang C Eur Radiol; 2020 Oct; 30(10):5337-5347. PubMed ID: 32385649 [TBL] [Abstract][Full Text] [Related]
13. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Yano Y; Yamamoto J; Kosuge T; Sakamoto Y; Yamasaki S; Shimada K; Ojima H; Sakamoto M; Takayama T; Makuuchi M Jpn J Clin Oncol; 2003 Jun; 33(6):283-7. PubMed ID: 12913082 [TBL] [Abstract][Full Text] [Related]
14. Mixed hepatocellular and cholangiocarcinoma: a rare tumor with a mix of parent phenotypic characteristics. Bergquist JR; Groeschl RT; Ivanics T; Shubert CR; Habermann EB; Kendrick ML; Farnell MB; Nagorney DM; Truty MJ; Smoot RL HPB (Oxford); 2016 Nov; 18(11):886-892. PubMed ID: 27546172 [TBL] [Abstract][Full Text] [Related]
15. Postresection Outcomes of Combined Hepatocellular Carcinoma-Cholangiocarcinoma, Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Yoon YI; Hwang S; Lee YJ; Kim KH; Ahn CS; Moon DB; Ha TY; Song GW; Jung DH; Lee JW; Hong SM; Yu ES; Lee SG J Gastrointest Surg; 2016 Feb; 20(2):411-20. PubMed ID: 26628072 [TBL] [Abstract][Full Text] [Related]
16. Clinicopathological characteristics of 15 patients with combined hepatocellular carcinoma and cholangiocarcinoma. Zuo HQ; Yan LN; Zeng Y; Yang JY; Luo HZ; Liu JW; Zhou LX Hepatobiliary Pancreat Dis Int; 2007 Apr; 6(2):161-5. PubMed ID: 17374575 [TBL] [Abstract][Full Text] [Related]
17. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA. Wang C; Chen C; Hu W; Tao L; Chen J Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206 [TBL] [Abstract][Full Text] [Related]
18. Clinical and pathological features of Allen's type C classification of resected combined hepatocellular and cholangiocarcinoma: a comparative study with hepatocellular carcinoma and cholangiocellular carcinoma. Tang D; Nagano H; Nakamura M; Wada H; Marubashi S; Miyamoto A; Takeda Y; Umeshita K; Dono K; Monden M J Gastrointest Surg; 2006; 10(7):987-98. PubMed ID: 16843869 [TBL] [Abstract][Full Text] [Related]